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Abstract
Objective: We used demographic and clinical data to design practical classification models for prediction of neurocognitive
impairment (NCI) in people with HIV infection.
Methods: The study population comprised 331 HIV-infected patients with available demographic, clinical, and
neurocognitive data collected using a comprehensive battery of neuropsychological tests. Classification and regression
trees (CART) were developed to obtain detailed and reliable models to predict NCI. Following a practical clinical approach,
NCI was considered the main variable for study outcomes, and analyses were performed separately in treatment-naı¨ve and
treatment-experienced patients.
Results: The study sample comprised 52 treatment-naı¨ve and 279 experienced patients. In the first group, the variables
identified as better predictors of NCI were CD4 cell count and age (correct classification [CC]: 79.6%, 3 final nodes). In
treatment-experienced patients, the variables most closely related to NCI were years of education, nadir CD4 cell count,
central nervous system penetration-effectiveness score, age, employment status, and confounding comorbidities (CC:
82.1%, 7 final nodes). In patients with an undetectable viral load and no comorbidities, we obtained a fairly accurate model
in which the main variables were nadir CD4 cell count, current CD4 cell count, time on current treatment, and past highest
viral load (CC: 88%, 6 final nodes).
Conclusion: Practical classification models to predict NCI in HIV infection can be obtained using demographic and clinical
variables. An approach based on CART analyses may facilitate screening for HIV-associated neurocognitive disorders and
complement clinical information about risk and protective factors for NCI in HIV-infected patients.
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Introduction
Neurocognitive impairment (NCI) is a concern in HIV
infection. Between one-third and two-thirds of HIV-infected
individuals experience this complication [1], which may lead to
impaired daily functioning [2], poor quality of life [3], difficulties
in clinical management (eg, poorer adherence to antiretroviral
therapy) [4], and even higher death rates [5]. Rapid, reliable, and
feasible detection of NCI is therefore a key element in the
therapeutic management of HIV-infected patients.
Neuropsychological test batteries are widely recommended for
assessment of neurocognitive status in HIV-infected persons [6–9].
However, they have been proposed mainly for comprehensive
evaluation of neurocognitive functioning, rather than rapid
detection of impairment in clinical practice. Definitive diagnosis
of HIV-associated neurocognitive disorders (HAND) is important,
and new approaches are necessary to facilitate screening [10].
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Access to neuropsychological resources varies depending on the
availability of care services for HIV-infected people, and practical
screening tools are not regularly used for detection of HIV-related
NCI. In this regard, additional methods may help to assist in the
identification of these disorders in HIV-infected individuals.
Demographic and clinical data are easily collected and could
help to identify NCI during the routine care of HIV-infected
patients, since they provide crucial information not only about
physical status, but also about central nervous system (CNS)
functioning [7,9]. Therefore, we recorded demographic and
clinical variables in order to design accurate and practical models
for predicting NCI in patients with HIV infection in daily clinical
practice. We used the classification and regression trees (CART)
methodology, which allowed us to obtain visual and easy-to-read
trees with variable accuracy for predicting the existence of NCI.
Methods
Design and Study Population
The study was based on data from 331 HIV-infected
outpatients attended at 7 HIV units in Barcelona, Catalonia,
Spain. Individuals were selected because they had voluntarily
undergone a comprehensive neuropsychological test battery,
which was offered routinely in the daily clinical practice of the
participating centres. Only participants with available demograph-
ic and clinical data were included. The remaining inclusion
criteria were age $18 years and positive results for HIV infection
in ELISA and Western-blot. Participants whose data were
incomplete for any of the study variables were excluded. All
participants provided their written informed consent to undergo
neurocognitive assessment, and the Ethics Committee of Germans
Trias i Pujol University Hospital (Badalona, Barcelona, Catalonia,
Spain) approved the study. Data were collected from September
2009 to March 2013.
Demographic and Clinical Assessments
Demographic variables included age, gender, route of trans-
mission, employment status, and years of education. Data were
self-reported.
The clinical variables collected were current CD4 cell count,
nadir CD4 cell count, plasma viral load, past highest viral load,
previous or no experience of antiretroviral therapy, current
antiretroviral therapy, CNS penetration-effectiveness (CPE) score,
previous treatment interruptions, time since HIV diagnosis, time
since initiation of the first regimen, time on the current regimen,
coinfection with hepatitis C virus (HCV), AIDS condition, and
existence of comorbidities with the potential to affect neurocog-
nitive performance. Data were retrieved from medical reports and
local clinical databases at the study sites. The CPE score was
calculated using the proposal by Letendre and collaborators [11].
Treatment interruption was defined as discontinuation of antiret-
roviral therapy for more than 15 days, regardless of the number of
discontinuations, and was recorded based on results from our
group revealing connections between previous interruptions and
worse neurocognitive status [12]. Potential confounding comor-
bidities were established mainly according to criteria of the
Frascati Group [7] and were treated as a categorical variable (yes/
no). The comorbidities included lifetime or current diagnosis of a
psychiatric disorder, receiving psychopharmacologic therapy, drug
or alcohol abuse, and prior or current CNS-related disease.
Emotional status, that is, specifically symptoms of depression and
anxiety, was assessed using the Beck Depression Inventory (BDI)
[13] and the State-Trait Anxiety Inventory (STAI) [14]. The
cognitive-affective subscale of the BDI was used to avoid biases
related to somatic symptoms [15].
Neurocognitive Assessment
Neurocognitive functioning was evaluated using a neuropsy-
chological battery composed of 14 tests covering 7 domains that
are recommended for assessment in HIV infection [7,9], as
follows: the Letter-Numbers and Digits tests of the Wechsler Adult
Intelligence Scale-III (WAIS-III) [16] for attention/working
memory; part A of the Trail Making Test (TMT) [17] and the
Symbol Digit Modalities Test (SDMT) [18] for information
processing speed; the California Verbal Learning Test - Part II
(CVLT) [19] for verbal memory and learning; part B of the TMT
[17], the Stroop Test [20], the Wisconsin Card Sorting Test
(WCST) [21], and the Tower of London (TOL) test [22] for
executive function; the Controlled Oral Word Association Test
(COWAT) [23] and the Animals test [24] for verbal fluency; and
the Grooved Pegboard Test (GPT) [25] for motor function. In
addition, the Vocabulary test of the WAIS-III [16] was used to
assess premorbid intelligence. Self-reported cognitive complaints
were also recorded and considered as a dichotomous categorical
variable (yes/no) in cases where patient reported symptoms of
impairment in memory, attention, or planning [26].
NCI was determined based on a neuropsychological criterion,
which was defined as performing at least 1 standard deviation
below the normative mean in at least 2 neurocognitive areas, as
extensively reported elsewhere [1,7,9]. Standardized T scores were
then used for all the analyses. These were obtained by
standardizing raw scores according to available normative data,
mainly covering age, gender, and years of education.
The classification of HAND was also used to describe the study
sample and was obtained by applying the Frascati criteria [7],
using interference in daily functioning in terms of self-reported
assessment, which was expressed as a dichotomous categorical
variable (yes/no).
Data Analyses
We used a tree-structured approach to provide useful classifi-
cation models for predicting NCI in HIV-infected individuals from
a clinical practice perspective. Specifically, we used CART
analyses, a methodology that generates rules for decisions
involving categorical outcomes [27].
CART analyses are based on the successive selection of a
variable and its value to subdivide the individuals comprising a
sample so as to better classify them. Consequently, the criteria for
subdivision are variables that make it possible to reduce the
difference in scores. This approach has several advantages. First,
CART analysis generates structured and visual classification rules,
which facilitate understanding for the study findings. Second, the
resulting outcomes depend on the different levels of accuracy.
Third, as for quantitative variables, CART provides specific cut-
off points that inform the user about key values that can affect the
final outcome. Fourth, as a non-parametric method, CART
analyses are not affected by the data distribution and thus enable
rigorous assumptions to be established without the undesirable
effects produced by outliers, collinearity, or heteroscedasticity.
Therefore these characteristics make it possible to apply classifi-
cation variables with different origins and a specific typology (e.g.,
categorical or continuous variables).
In our study, the presence of NCI was the main study variable
and was therefore considered a final endpoint in the classification
models, namely, presence or absence of a disorder. The cross-
validation method was used to determine the optimal size of the
tree as a function of misclassification and of the cost-complexity
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parameter, depending on which the initial tree was pruned to
obtain a simpler classification rule.
Because we followed a practical clinical approach, models were
elaborated separately for antiretroviral treatment-naı¨ve and
treatment-experienced patients, and we finally selected those with
the greatest accuracy and simplicity according to the accuracy of
classification found and the number of terminal nodes displayed.
All study analyses were performed using SPSS for Windows,
version 15.0 (Chicago, SPSS Inc.) and R, version 2.11 (http://
www.r-project.org).
Results
Treatment-Naı¨ve Patients
Of the total sample of 331 patients, 52 were treatment-naı¨ve.
Patients in this group were predominantly men (85%), middle-
aged (median [interquartile range]: 35 years [28–42]), with a
median viral load of 17,000 copies/mL (4,950–61,250), current
CD4 count of 437 cells/mL (292–693), and nadir CD4 count of
416 cells/mL (232–597). NCI was present in 21 of the 52
treatment-naı¨ve individuals (40%), and cognitive complaints were
reported in 11 of the 21 (52%). The remaining demographic,
clinical, and neurocognitive characteristics are shown in Table 1.
The highest correct classification obtained from the trees was
83.6% in a model with 7 final nodes. This included 5 main
variables: CD4 cell count, age, employment status, nadir CD4 cell
count, and current CD4 cell count (by order of relevance). The
simplest tree had 3 final nodes and included only CD4 cell count
and age as predictive variables (Figure 1). The percentage of
correct classification obtained from this tree was 79.6%. As for
specific cut-off points, NCI was detected when the CD4 cell count
was ,123 cells/mL. When the CD4 cell count was $123 cells/mL,
presence of of NCI varied with age: age $45 years was associated
with impairment, and age ,45 years was associated with non-
altered functioning.
Treatment-Experienced Patients
A total of 279 patients had previously received antiretroviral
therapy and were all currently on treatment. Most were men
(83%) and middle-aged (median, 44 years [40–50]), with an
undetectable viral load (86%), a median current CD4 count of 539
cells/mL (383–737), and a nadir CD4 count of 189 cells/mL (87–
313). NCI was present in 140 individuals (50%), of whom 71 (53%)
reported complaints. The remaining characteristics are displayed
in Table 1.
The highest correct classification in the trees obtained was
83.5% in a model with 12 final nodes, including a total of 8
variables: years of education, CPE score, nadir CD4 cell count,
age, employment status, years since HIV diagnosis, years on
antiretroviral therapy, and presence of potential confounding
comorbidities.
Pruning the initial model provided a simple tree that did not
substantially increase the misclassification rate. In a model with 7
final nodes and 6 variables, a correct classification of 82.1% was
reached. The variables included in this tree were education, CPE
score, nadir CD4 cell count, age, employment status, and
existence of comorbidities (Figure 2). Years of education was
the most relevant parameter. When this value was $10 years, the
nadir CD4 cell count was the variable that established the
presence of NCI: counts of $308 cells/mL were associated with
absence of dysfunction and lower values with normal performance.
However, when duration of education was ,10 years, CPE score
was found at the second level of prediction. In this regard, values
of $8.5 were associated with impaired functioning. At a lower
CPE score, age was revealed as a next parameter. An age $59
years was associated with normal performance; in younger
patients, employment status was the variable that established the
presence of NCI. Unemployment was associated with impairment;
employment was associated with the existence of comorbidities at
the lowest level of this model. Impairment was found in the
presence of comorbidities and normal functioning in the absence
of comorbidities.
In our search for a homogeneous subset of patients, we also
studied individuals with an undetectable viral load (n = 240). The
simplest model from the trees comprised 3 nodes and 2 variables
and had a 73.4% correct classification. Months on current
antiretroviral treatment and years since HIV diagnosis were the
variables included. NCI was not predicted when patients had been
on current therapy for $5 months. In patients with ,5 months on
treatment, the number of years since HIV diagnosis determined
the presence of NCI. Impairment was found in people diagnosed
with HIV infection$13 years age, but not in those diagnosed,13
years ago (Figure 3).
Analysis of an even more homogenous subgroup—individuals
with an undetectable viral load and no presence of potential
confounding comorbidities (n = 148)—revealed remarkable accu-
racy with a correct classification of 88%, included 6 final nodes,
and comprised 4 main predicting variables: nadir CD4 cell count,
current CD4 cell count, months on current treatment, and past
highest viral load (Figure 4). Nadir CD4 cell count was the first
predictive variable. When this was $225 cells/mL, the current
CD4 cell count was the second explanatory variable: normal
functioning was observed at values of $457 cells/mL, and
impairment was observed at lower values. With respect to nadir
counts ,225 cells/mL, time on current treatment and past highest
viral load were associated with the presence of NCI. When time on
treatment was ,5 months, NCI was detected. In contrast, when
time on treatment was between $5 and ,13 months, impairment
was not detected. And finally, when time on therapy was $13
months, past highest viral load value was associated with
dysfunction. As for viral load, values $112,142 copies/mL were
associated with NCI; lower values indicated normal performance.
Discussion
We used a practical approach to analyze demographic and
clinical data that could predict NCI in patients with HIV infection.
Our data complement current knowledge on HIV-associated NCI,
a major concern in the therapeutic management of HIV-infected
patients. Different classification models were obtained, and we
provide those that are potentially more useful in clinical practice,
specifically in terms of accuracy and simplicity. Accuracy was
based on the level of correct classification, and simplicity on the
number of variables included in the models and the number of
final nodes.
In our sample of antiretroviral-naı¨ve patients, the variables most
significantly identified as predictors of impairment were CD4 cell
count and age. CD4 cell count is widely acknowledged as an
optimal marker of progression of HIV infection and our
observations confirm this fact. As our approach was clinical, we
applied graphical statistical methodology, which provided clear
and specific visual study outcomes. Accordingly, classification trees
obtained for naı¨ve patients revealed cut-offs of 123 cells/mL and
age 45 years. The value for the CD4 cut-off is consistent with
previous findings indicating comparable links between worse
immunological status and existence of neurocognitive disruption,
particularly in advanced immunosuppression [28,29]. Similarly,
older age is considered a risk factor for major cognitive changes in
Predicting HIV Neurocognitive Impairment
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HIV-infected individuals, although a representative cut-off point
has not been established in this regard [30,31]. Nevertheless, most
thresholds investigated have consisted of a cut-off at around age 50
years, which is fairly close to our results.
In patients on antiretroviral therapy, relevant parameters were
years of education, nadir CD4 cell count, and CPE score.
Education appeared at the first level of prediction. In fact, even in
more complex models (.10 final nodes, not shown in the present
report), level of education proved consistently relevant for
determination of NCI. Greater education has been shown to act
as a protective factor in the development of neurocognitive
complications [32]. Irrespective of HIV infection, this factor has
been considered a key variable in CNS-related diseases such as
brain injury [33], Alzheimer’s disease [34], and Parkinson’s disease
[35]. Similarly, nadir CD4 cell count is a key predictor of NCI in
HIV infection [36–38]. Our observations confirm this association,
suggesting a significant cut-off of ,308 cells/mL for onset of NCI.
In contrast, for the CPE score, previous findings do not appear to
support ours [39–43]. As described above, our results suggest that
higher CPE scores may be associated with a higher probability of
Table 1. Characteristics of the study sample.
Treatment-naı¨ve patients
(n = 52)
Treatment-experienced patients
(n = 279)
Age, years 35 (28–42) 44 (40–50)
Male,% 85 83
Infection route,%
Injecting drug user 4 21
Heterosexual 15 19
Men who have sex with men 65 48
Other 4 1
Unknown 12 11
Education, years 12 (10–15) 12 (8–15)
Time since HIV diagnosis, years 1 (0–3) 11 (6–17)
On ART,% - 100
Time on treatment, years - 8 (3–12)
Time on current regimen, months - 12 (0–24)
Previous ART interruptions,% a - 36
CD4 cell count, cells/mL 437 (292–693) 539 (383–737)
Nadir CD4 cell count, cells/mL 416 (232–597) 189 (87–313)
Plasma viral load, copies/mL 17,000 (4,950–61,250) 50 (50–50)
Undetectable viral load,% b 5 86
Past highest viral load, copies/mL 41,000 (5,861–132,500) 92,500 (17,000–240,000)
Coinfection with HCV,% 9 24
Standardized depression score c 52 (42–58) 48 (37–57)
Standardized anxiety score d 52 (41–59) 48 (40–57)
Standardized premorbid intelligence score e 53 (43–60) 56 (50–60)
Neurocognitive impairment,% 40 50
HAND,% f
ANI 50 53
MND 50 46
HAD 0 1
Cognitive complaints,% f 52 53
Potential confounding comorbidities,% g 32 39
Data expressed as median (interquartile range), except when indicated otherwise.
Standardized scores are adjusted for age, gender and education, according to available normative data.
Abbreviations: ANI, asymptomatic neurocognitive impairment; ART, antiretroviral therapy; HAD, HIV-associated dementia; HAND, HIV-associated neurocognitive
disorder; HCV, hepatitis C virus; MND, mild neurocognitive disorder.
aART interruption defined as discontinuing therapy.15 days at any time for any reason in the past.
bUndetectable at #40 copies/mL level.
cDepression scores based on the Beck Depression Inventory test.
dAnxiety scores based on the State-Trait Anxiety Inventory.
ePremorbid intelligence scores based on the Vocabulary test from the Wechsler Adult Intelligence Scale-III.
fFrom patients with neurocognitive impairment.
gPotential confounding comorbidities defined as lifetime or current diagnosis of a psychiatric disorder, receiving psychopharmacologic therapy, drug or alcohol abuse,
and prior or current CNS-related disease.
doi:10.1371/journal.pone.0107625.t001
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impairment. In this sense, our hypotheses have been put forward
in a clinical setting that is more difficult to manage, where more
antiretrovirals are prescribed and more antiretroviral-induced
neurotoxicity may exist. Nonetheless, our objectives and study
design have not enabled us to draw solid findings. Conclusions on
the CPE score should be obtained from prospective studies
specifically designed to investigate this topic, after controlling for
variables related to antiretroviral therapy and the characteristics of
the population studied [9]. A similar effect occurs with age, since
our results indicate that it could protect against NCI. Successful
aging and a more robust cognitive reserve could act as protective
factors, as reported elsewhere [44,45]; however, again, we are
unable to draw further conclusions. Our findings also show the
importance of employment status and potential confounding
comorbidities as determinants of neurocognitive dysfunction. Both
features are consistent with previous observations on connections
between active employment status and greater protection of CNS
functioning [46], and between presence of potential comorbidities
for NCI and impaired cognitive functioning [7].
We performed separate analyses of patients with undetectable
viral load and patients with an undetectable viral load and no
confounding comorbidities in order to investigate further the
mechanisms of HIV-associated NCI. Significant differences in
time variables were found in patients with an undetectable viral
load: time on current antiretroviral treatment and time since HIV
diagnosis were the main predictors. Both variables have previously
been shown to play a key role in HIV-related cognitive decline,
with theoretical advantages for longer time on therapy and
disadvantages for a more extended time since HIV diagnosis
[11,47]. In the case of individuals with an undetectable viral load
and no confounding comorbidities—apart from time on current
treatment and nadir CD4 cell count—current CD4 cell count and
past highest viral load were also key variables. Thus, according to
CART, we confirmed the role of factors traditionally linked to
cognitive decline in HIV infection.
Our study has several limitations. First, although we aimed to
obtain a large sample, our sample size was reduced by performing
separate analyses of 2 groups (treatment-naı¨ve and treatment-
experienced patients) and because of the number of subjects
studied for each subgroup in the final nodes. As mentioned above,
the statistical methodology applied was based on CART;
consequently, the sizes for the category groups were further
reduced. A second limitation is the clinical variables analyzed.
Because we used available medical data from the participating
centres, valuable supplementary clinical information (even if not
Figure 1. Classification model for treatment-naı¨ve patients
(n = 52). Correct classification: 79.6%, 3 final nodes.
doi:10.1371/journal.pone.0107625.g001
Figure 2. Classification model for treatment-experienced patients (n = 279). Correct classification: 82.1%, 7 final nodes.
doi:10.1371/journal.pone.0107625.g002
Figure 3. Classification model for treatment-experienced
patients with undetectable viral load (n = 240). Correct classi-
fication: 73.4%, 3 final nodes.
doi:10.1371/journal.pone.0107625.g003
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systematically gathered) was ignored for the purposes of the study.
Examples include cardiovascular risk factors and hormonal
markers, which are known to be associated with cognitive
dysfunction in both the general population and HIV-infected
individuals. Another limitation is the use of NCI as a primary
outcome measure, instead of a specific HAND. This approach was
adopted because of the clinical utility of the dichotomous character
of NCI, and also due to the controversy surrounding the
distinction between asymptomatic NCI (ANI) and mild neurocog-
nitive disorder (MND). Nevertheless, the HAND classification
would have made it possible to integrate valuable information
about the severity of the impairment.
Despite these limitations, and considering that our sample was
from a single geographic area, the current work presents
significant strengths. First, the models provided visual, easy-to-
read outcomes that can be used immediately in clinical practice.
Second, specific numeric cut-off points are offered for quantitative
variables, also a major advantage in daily clinical practice. And
third, different models are provided according to the level of
accuracy and simplicity. Hence, clinicians and care providers are
able to decide which models fit best in a specific setting. In fact, the
degree of accuracy of the classifications was high. If we compare
this feature with the accuracy provided by other screening tools for
HIV-related NCI, it is clearly significant. Therefore, although the
methodology presented should be seen as a novel approach when
screening for HAND, the results generated can substantially help
in the management and monitoring of neurocognitive complica-
tions in HIV-infected persons, particularly in those scenarios
where clinical resources are limited. We fully recommend the
application of neuropsychological test batteries for the rigorous
assessment of neurocognitive functioning in HIV-infected individ-
uals, but now we offer a potential screening method to identify the
existence of risk and protective factors for NCI, considered as a
supplementary resource for the therapeutic management of
HAND.
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